HC Wainwright & Co. maintains Buy rating on Tyra Biosciences, $29 price target

Tyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.

Tyra priced an offering of 9.08M common shares at $22.03 each and 9.08M pre-funded warrants at $22.029 each, expected to raise $400M. Underwriters bought at $20.7082 per unit. Proceeds will support drug development and corporate purposes, according to the company.

Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.

Tyra Biosciences (TYRA) stock rose 9.8% after announcing a $400M public offering at $22.03 per share, with proceeds funding clinical programs. The offering was led by RA Capital and major banks, following positive Phase 2 trial results. The company aims to advance its dabogratinib 3x3 strategy, targeting specific cancers and achondroplasia.

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

Tyra Biosciences (NASDAQ:TYRA) shares fell 21.6% after Phase 2 trial results for dabogratinib showed an 86% overall response rate in patients with target exposure, but a 57% complete response rate at 60 mg, below analyst expectations of 70-80%. The company plans to advance to Phase 3 development and expand the study to a 70 mg cohort. Initial upper tract urothelial cancer study results were positive.